How digital therapeutics are reshaping the standard of care in mental health. Interview with Hannes Klöpper, CEO of HelloBetter.
There are millions of people worldwide who suffer from some form of mental illness but have no access to effective care in a timely manner. The pandemic has accelerated the need for on demand evidence-based self-help mental health DTx and behavioural health programs to improve population’s wellbeing. What is the reality check in this rapidly Learn more...
Drawing the curtain on innovation theatrics – Do startup accelerators have more bark than bite?
The accelerator model has become a popular innovation vehicle for many corporates looking to connect with startups. If done right, these programs can deliver substantial upside to both parties as startups receive the resources and funding to scale while corporates access new technologies and business models. However, accelerators have often fallen short of this ideal Learn more...
Launching regulated SaMD and DTx in months – Mission Possible! Interview with Kal Patel, MD, CEO & Co-Founder of BrightInsight.
Digital health presented biopharma and medtech companies with an opportunity to design new commercial models by venturing into partnerships to accelerate clinical trials, offer personalized DTx, and improve adherence within the swim lanes of their core businesses. Leveraging digital technologies, minimizing risk and accelerating time to market in a regulatory compliant environment is crucial for Learn more...
Digital health has grown in the wake of COVID-19… but which segments were most impacted?
One year into the pandemic, some industries have benefited from the shift to a remote-first approach – including digital health. But even within this industry, not all subsegments have been affected equally. Which business models within digital health have experienced the most growth? And which continue to have high potential, even after the COVID pandemic Learn more...
Why are digital therapeutic companies not connecting to the traditional healthcare system by integrating with an EMR.
Currently, the world of the traditional EMR system and the world of digital therapeutic companies (DTx) do not integrate, and the reason is that there are significant barriers preventing integration. There are four main barriers today that prevent further integration. A new approach is needed. When looking at EMR integration, there are two worlds. On Learn more...
How covid-19 took the global digital health industry by surprise
Around the world, the digital health industry largely underestimated the positive impact that the COVID-19 pandemic would have on their business. R2G released a new survey summarizing these impacts, and other changes in the industry since the beginning of the pandemic. The COVID-19 pandemic has impacted lives, societies, and economies around the world. Seemingly overnight, Learn more...
DiGA listing is not enough! Finding the right channel to reach doctors and patients in Germany
The DiGA Fast Track provides both a reimbursement model and quality stamp for digital health solutions looking to enter the German market. However, download rates of recently approved solutions show that listing as DiGA alone does not ensure a high adoption rate. Companies will therefore have to develop a comprehensive market entry strategy and select Learn more...
How Happify Health supports the mental and physical health of 20 million people with DTx & patient care solutions. Interview with Christopher Wasden, Head of Happify DTx.
The pandemic has enormously increased the demand for access to personalized mental health services and brought digital mental health solutions and digital therapeutics programs to the frontline of global health investments. Millions of dollars were invested in innovative digital health providers to scale mental health care delivery and chronic disease management programs to improve population Learn more...
Four main reasons of why digital biomarkers are hot
Digital biomarkers are becoming a hot topic. Investors are lining up. Pharma companies are eager to secure the best digital biomarker development companies to support their clinical and commercial initiatives. But what makes the digital biomarkers so attractive? There are four reasons of why digital biomarkers are getting the attention of the investors. Until the Learn more...